2023
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.Peer-Reviewed Original ResearchRecognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut
Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, Leventhal J, Morford K, Sue K. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. Journal Of Addiction Medicine 2023, 17: 739-741. PMID: 37934550, DOI: 10.1097/adm.0000000000001198.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersDrug useCase report presentsIndex of suspicionInjection drug useDrug supplyCare management strategiesHarm reduction strategiesOverdose presentationsCutaneous manifestationsWithdrawal syndromeClinical complicationsCase reportIntravenous useWound carePatientsTreatment of woundsInfectious diseasesChronic woundsXylazineSkin woundsWoundsMore reportingDiagnosisPD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens
Damo M, Hornick N, Venkat A, William I, Clulo K, Venkatesan S, He J, Fagerberg E, Loza J, Kwok D, Tal A, Buck J, Cui C, Singh J, Damsky W, Leventhal J, Krishnaswamy S, Joshi N. PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. Nature 2023, 619: 151-159. PMID: 37344588, PMCID: PMC10989189, DOI: 10.1038/s41586-023-06217-y.Peer-Reviewed Original ResearchConceptsEffector CD8 T cellsCD8 T cellsAntigen-specific effector CD8 T cellsAntigen-specific CD8 T cellsAntigen-expressing cellsT cell tolerancePD-1T cellsAdverse eventsCell toleranceCD8 T cell toleranceImmune-related adverse eventsPeripheral T cell repertoirePeripheral T cell toleranceNon-lesional skinT cell repertoireT-cell antigensPeripheral toleranceCheckpoint receptorsSkin biopsiesLocal infiltrationLocal pathologyCell repertoireMouse modelSkin toleranceMalignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database
Yumeen S, Mirza F, Mirza H, Zogg C, Leventhal J, Cohen J. Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database. Journal Of The American Academy Of Dermatology 2023, 89: 843-846. PMID: 37343827, DOI: 10.1016/j.jaad.2023.05.090.Peer-Reviewed Original ResearchImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceCrusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis.
Olamiju B, Leventhal J, Vesely M. Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis. Cutis 2023, 111: e44-e47. PMID: 37406327, DOI: 10.12788/cutis.0794.Peer-Reviewed Original ResearchConceptsCrusted scabiesMedication-induced immunosuppressionTreatment of granulomatosisBone marrow transplantationDiagnosis of scabiesVar hominisIatrogenic immunosuppressionBroad differentialMarrow transplantationAutoimmune diseasesSolid organsRare caseSevere formPatientsImmunosuppressionErythrodermaScabiesInfectionEctoparasitic infectionsPolyangiitisGranulomatosisTreatmentMyelosuppressionTransplantationDiseaseHistopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanoma
Belzer A, Becerra C, Clune J, Malik M, Leventhal J, Cowper S, Johnson R. Histopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanoma. Journal Of Cutaneous Pathology 2023, 50: 471-474. PMID: 36645720, DOI: 10.1111/cup.14376.Peer-Reviewed Original ResearchThe effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy
Belzer A, Mortlock R, Pach J, Cohen J, Leventhal J. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy. Journal Of The American Academy Of Dermatology 2023, 88: 1198-1200. PMID: 36634749, PMCID: PMC10121758, DOI: 10.1016/j.jaad.2023.01.002.Peer-Reviewed Original ResearchSpectrum of Dermatologic Adverse Events Associated With Amivantamab Use
Belzer A, Nguyen M, Talsania A, Haldas J, Smith J, Leventhal J. Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatology 2023, 159: 109-111. PMID: 36416832, PMCID: PMC9685543, DOI: 10.1001/jamadermatol.2022.4466.Peer-Reviewed Original Research
2022
The spectrum of cutaneous immune-related adverse events in patients with skin of color
Belzer A, Mortlock R, Olamiju B, Olino K, Cohen J, Leventhal J. The spectrum of cutaneous immune-related adverse events in patients with skin of color. Journal Of The American Academy Of Dermatology 2022, 88: 1156-1158. PMID: 36470309, PMCID: PMC10838520, DOI: 10.1016/j.jaad.2022.11.051.Peer-Reviewed Original ResearchDupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression
Ahmad M, Murphy M, Damsky W, Leventhal J. Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. International Journal Of Dermatology 2022, 62: e424-e426. PMID: 36468831, DOI: 10.1111/ijd.16538.Peer-Reviewed Original ResearchConsensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey
Wilson BN, Shah R, Menzer C, Aleisa A, Sun MD, Kwong BY, Kaffenberger BH, Seminario‐Vidal L, Barker CA, Stubblefield MD, Romesser PB, Fabbrocini G, Alam M, Abdulla F, Dulmage B, Sibaud V, Anadkat M, Mazer J, Parikh D, McLellan B, Cartier H, Pugliese S, Wolkerstorfer A, Laubach H, LeBoeuf N, Leventhal J, Wan DC, Choi J, Tran T, Anderson RR, Markova A, Rossi A. Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey. British Journal Of Dermatology 2022, 187: 1054-1056. PMID: 36047980, PMCID: PMC10087782, DOI: 10.1111/bjd.21852.Peer-Reviewed Original ResearchMucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1)
Belzer A, Silber A, Mehra S, Gilani S, Leventhal JS. Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1). British Journal Of Dermatology 2022, 187: e168-e168. PMID: 35633104, DOI: 10.1111/bjd.21654.Peer-Reviewed Case Reports and Technical NotesPsoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series
Ahearn EL, Belzer A, Cohen SR, Leventhal JS, Deverapalli SC. Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series. International Journal Of Dermatology 2022, 62: e411-e414. PMID: 36271737, DOI: 10.1111/ijd.16464.Peer-Reviewed Original ResearchTreatment of myelodysplasia‐associated reactive, non‐interstitial granulomatous dermatitis with hydroxychloroquine
Choi R, Bhullar S, Glusac E, Podoltsev N, Leventhal J. Treatment of myelodysplasia‐associated reactive, non‐interstitial granulomatous dermatitis with hydroxychloroquine. International Journal Of Dermatology 2022, 62: e398-e399. PMID: 36214463, DOI: 10.1111/ijd.16441.Peer-Reviewed Case Reports and Technical NotesJanus kinase‐signal transducers and activators of transcription (JAK–STAT) activation in anti‐programmed death‐1 (PD‐1) therapy—Associated granuloma annulare: a case series
Choi R, Wang JX, Damsky W, Wang A, Galan A, Leventhal J. Janus kinase‐signal transducers and activators of transcription (JAK–STAT) activation in anti‐programmed death‐1 (PD‐1) therapy—Associated granuloma annulare: a case series. International Journal Of Dermatology 2022, 62: e323-e325. PMID: 35933688, PMCID: PMC9902571, DOI: 10.1111/ijd.16375.Peer-Reviewed Original ResearchCutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
Pach J, Leventhal J. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. Critical Reviews In Immunology 2022, 42: 1-20. PMID: 37022356, DOI: 10.1615/critrevimmunol.2023046895.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsCheckpoint inhibitorsT cellsAdverse eventsCutaneous immune-related adverse eventsImmune checkpoint inhibitor therapyInhibition of T cellsOveractivation of T cellsCheckpoint inhibitor therapyImmune checkpoint inhibitorsCutaneous adverse eventsStevens-Johnson syndromeCutaneous autoimmune diseasesToxic epidermal necrolysisPre-existing diseaseLife-threatening eruptionsInhibitor therapyTreatment interruptionImmune dysregulationImmune surveillanceMaculopapular eruptionEpidermal necrolysisAutoimmune diseasesBullous dermatosisAntitumor activity
2021
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.
Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. Journal Of Drugs In Dermatology 2021, 20: 3ss-s19. PMID: 34491030, DOI: 10.36849/jdd.6229.Peer-Reviewed Original ResearchConceptsCutaneous adverse eventsCancer patientsAnticancer treatmentEvidence-based algorithmNumber of patientsQuality of studiesAdverse eventsOncology patientsPatients' qualityPatient outcomesSun protection productsSurvivors' qualitySkincare regimenCounter agentsSkin conditionsPatientsHealthcare providersHealthy skinMultidisciplinary teamCancer treatmentAdvanced providersGeneral measuresTreatmentDelphi approachSkincare formulationsRadiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original ResearchSubcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma
Pach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatology 2021, 157: 468-469. PMID: 33688919, DOI: 10.1001/jamadermatol.2021.0058.Peer-Reviewed Original Research